Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 14/05/2019 | Bisantrene AML trial to start in Israel | Download |
| 24/04/2019 | Bisantrene IND Update | Download |
| 12/04/2019 | Appendix 4C - quarterly | Download |
| 25/03/2019 | Race files Bisantrene IND with FDA | Download |
| 13/03/2019 | Appendix 3B | Download |
| 27/02/2019 | Appendix 4D & Half-Year Financial Statements | Download |
| 25/02/2019 | Principal Investigator appointed for Bisantrene | Download |
| 14/02/2019 | Appendix 3Y-Dr William Garner | Download |
| 12/02/2019 | Change in substantial holding | Download |
| 12/02/2019 | Change of Director's Interest Notice-Mr Chris Ntoumenopoulos | Download |
ASX: RAC
Price
Latest News
Bisantrene investigator-initiated AML trial to start in Israel
Race Oncology has announced that it has signed an agreement to conduct a trial of Race’s
Investigational New Drug application filed with FDA
Race Oncology has announced the US Food and Drug Administration has received its
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal
Don't miss important updates
Get the latest news & announcement and stay up-to-date.